Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
- Conditions
- LeukemiaMedulloblastoma
- Registration Number
- NCT00231712
- Lead Sponsor
- Julius-Maximilians University
- Brief Summary
The purpose of this study is to conduct an analysis of the influences of
1. conventional chemotherapy
2. high-dose chemotherapy followed by autologous stem cell transplant
3. high-dose chemotherapy followed by allogeneic stem cell transplant on the recovery of the immune system.
Detailed analysis will help to better understand the pathways of recovery of the immune system following chemotherapy as well as the pathways of recovery of the immune system following autologous or allogeneic stem cell transplantation.
- Detailed Description
Detailed analysis will be performed at preselected time points following therapy by
* standard flow cytometry in combination with intracellular cytokine/antigen staining
* spectratype analysis
* TREC assays
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- Acute leukemia treated according to current ALL-BFM 2002 protocol
- Solid tumor treated according to current GPOH-protocol
- Medulloblastoma treated according to HIT-2000 protocol
- High-dose chemotherapy followed by autologous stem cell transplantation
- High-dose chemotherapy followed by allogeneic stem cell transplantation
- Written consent according to our institutional guidelines
- No written consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Children's Hospital Pedaitric Oncology
🇩🇪Wuerzburg, Germany